Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
- PMID: 22351618
- PMCID: PMC3319317
- DOI: 10.1158/1055-9965.EPI-11-0888
Common variants at the 19p13.1 and ZNF365 loci are associated with ER subtypes of breast cancer and ovarian cancer risk in BRCA1 and BRCA2 mutation carriers
Abstract
Background: Genome-wide association studies (GWAS) identified variants at 19p13.1 and ZNF365 (10q21.2) as risk factors for breast cancer among BRCA1 and BRCA2 mutation carriers, respectively. We explored associations with ovarian cancer and with breast cancer by tumor histopathology for these variants in mutation carriers from the Consortium of Investigators of Modifiers of BRCA1/2 (CIMBA).
Methods: Genotyping data for 12,599 BRCA1 and 7,132 BRCA2 mutation carriers from 40 studies were combined.
Results: We confirmed associations between rs8170 at 19p13.1 and breast cancer risk for BRCA1 mutation carriers [HR, 1.17; 95% confidence interval (CI), 1.07-1.27; P = 7.42 × 10(-4)] and between rs16917302 at ZNF365 (HR, 0.84; 95% CI, 0.73-0.97; P = 0.017) but not rs311499 at 20q13.3 (HR, 1.11; 95% CI, 0.94-1.31; P = 0.22) and breast cancer risk for BRCA2 mutation carriers. Analyses based on tumor histopathology showed that 19p13 variants were predominantly associated with estrogen receptor (ER)-negative breast cancer for both BRCA1 and BRCA2 mutation carriers, whereas rs16917302 at ZNF365 was mainly associated with ER-positive breast cancer for both BRCA1 and BRCA2 mutation carriers. We also found for the first time that rs67397200 at 19p13.1 was associated with an increased risk of ovarian cancer for BRCA1 (HR, 1.16; 95% CI, 1.05-1.29; P = 3.8 × 10(-4)) and BRCA2 mutation carriers (HR, 1.30; 95% CI, 1.10-1.52; P = 1.8 × 10(-3)).
Conclusions: 19p13.1 and ZNF365 are susceptibility loci for ovarian cancer and ER subtypes of breast cancer among BRCA1 and BRCA2 mutation carriers.
Impact: These findings can lead to an improved understanding of tumor development and may prove useful for breast and ovarian cancer risk prediction for BRCA1 and BRCA2 mutation carriers.
©2012 AACR.
Conflict of interest statement
The content of this manuscript does not necessarily reflect the views or policies of the National Cancer Institute or any of the collaborating centers in the BCFR, nor does mention of trade names, commercial products, or organizations imply endorsement by the US Government or the BCFR. No potential conflicts of interest are disclosed.
Figures



Similar articles
-
Common variants at 12p11, 12q24, 9p21, 9q31.2 and in ZNF365 are associated with breast cancer risk for BRCA1 and/or BRCA2 mutation carriers.Breast Cancer Res. 2012 Feb 20;14(1):R33. doi: 10.1186/bcr3121. Breast Cancer Res. 2012. PMID: 22348646 Free PMC article.
-
Common alleles at 6q25.1 and 1p11.2 are associated with breast cancer risk for BRCA1 and BRCA2 mutation carriers.Hum Mol Genet. 2011 Aug 15;20(16):3304-21. doi: 10.1093/hmg/ddr226. Epub 2011 May 18. Hum Mol Genet. 2011. PMID: 21593217 Free PMC article.
-
Genome-wide association study in BRCA1 mutation carriers identifies novel loci associated with breast and ovarian cancer risk.PLoS Genet. 2013;9(3):e1003212. doi: 10.1371/journal.pgen.1003212. Epub 2013 Mar 27. PLoS Genet. 2013. PMID: 23544013 Free PMC article.
-
Genetic modifiers of cancer risk for BRCA1 and BRCA2 mutation carriers.Ann Oncol. 2011 Jan;22 Suppl 1:i11-7. doi: 10.1093/annonc/mdq660. Ann Oncol. 2011. PMID: 21285145 Review.
-
Modifiers of breast and ovarian cancer risks for BRCA1 and BRCA2 mutation carriers.Endocr Relat Cancer. 2016 Oct;23(10):T69-84. doi: 10.1530/ERC-16-0277. Epub 2016 Aug 15. Endocr Relat Cancer. 2016. PMID: 27528622 Review.
Cited by
-
Molecular Cytogenomic Characterization of the Murine Breast Cancer Cell Lines C-127I, EMT6/P and TA3 Hauschka.Int J Mol Sci. 2020 Jul 1;21(13):4716. doi: 10.3390/ijms21134716. Int J Mol Sci. 2020. PMID: 32630352 Free PMC article.
-
ZNF-mediated resistance to imatinib mesylate in gastrointestinal stromal tumor.PLoS One. 2013;8(1):e54477. doi: 10.1371/journal.pone.0054477. Epub 2013 Jan 25. PLoS One. 2013. PMID: 23372733 Free PMC article.
-
The effect of personal medical history and family history of cancer on the uptake of risk-reducing salpingo-oophorectomy.Fam Cancer. 2015 Dec;14(4):539-44. doi: 10.1007/s10689-015-9827-7. Fam Cancer. 2015. PMID: 26264902 Free PMC article.
-
Identification of six new susceptibility loci for invasive epithelial ovarian cancer.Nat Genet. 2015 Feb;47(2):164-71. doi: 10.1038/ng.3185. Epub 2015 Jan 12. Nat Genet. 2015. PMID: 25581431 Free PMC article.
-
Identification of key genes participating in copper-diethyldithiocarbamate-related cell death process and predicting the development of prostate cancer.Discov Oncol. 2024 Oct 3;15(1):519. doi: 10.1007/s12672-024-01390-6. Discov Oncol. 2024. PMID: 39361158 Free PMC article.
References
Publication types
MeSH terms
Substances
Grants and funding
- U01 CA069417/CA/NCI NIH HHS/United States
- CA128978/CA/NCI NIH HHS/United States
- U01 CA69417/CA/NCI NIH HHS/United States
- N02PC45022-46/PC/NCI NIH HHS/United States
- R01 CA083855/CA/NCI NIH HHS/United States
- P30 CA051008/CA/NCI NIH HHS/United States
- 15007/CRUK_/Cancer Research UK/United Kingdom
- C1287/A11990/CRUK_/Cancer Research UK/United Kingdom
- U01 CA069446/CA/NCI NIH HHS/United States
- 10124/CRUK_/Cancer Research UK/United Kingdom
- CA-06503/CA/NCI NIH HHS/United States
- U01 CA069638/CA/NCI NIH HHS/United States
- CA116201/CA/NCI NIH HHS/United States
- 11174/CRUK_/Cancer Research UK/United Kingdom
- P30-CA051008/CA/NCI NIH HHS/United States
- C5047/A8385/CRUK_/Cancer Research UK/United Kingdom
- U01 CA069467/CA/NCI NIH HHS/United States
- 11022/CRUK_/Cancer Research UK/United Kingdom
- N02-CP-11019-50/CP/NCI NIH HHS/United States
- CAPMC/ CIHR/Canada
- C12292/A11174/CRUK_/Cancer Research UK/United Kingdom
- U01 CA069398/CA/NCI NIH HHS/United States
- R01 CA128978/CA/NCI NIH HHS/United States
- N02 CP011019/CP/NCI NIH HHS/United States
- N02 CP065504/CP/NCI NIH HHS/United States
- P50 CA116201/CA/NCI NIH HHS/United States
- U01 CA113916/CA/NCI NIH HHS/United States
- U01 CA069631/CA/NCI NIH HHS/United States
- U01 CA69398/CA/NCI NIH HHS/United States
- R01-CA083855/CA/NCI NIH HHS/United States
- 5U01CA113916/CA/NCI NIH HHS/United States
- U01 CA69638/CA/NCI NIH HHS/United States
- P01 CA130818/CA/NCI NIH HHS/United States
- R01 CA102776/CA/NCI NIH HHS/United States
- U01 CA69446/CA/NCI NIH HHS/United States
- U01 CA69631/CA/NCI NIH HHS/United States
- U01CA69631/CA/NCI NIH HHS/United States
- 10118/CRUK_/Cancer Research UK/United Kingdom
- C1287/A10118/CRUK_/Cancer Research UK/United Kingdom
- P01 CA130818-02A1/CA/NCI NIH HHS/United States
- U01 CA69467/CA/NCI NIH HHS/United States
LinkOut - more resources
Full Text Sources
Medical
Molecular Biology Databases
Miscellaneous